Mr. Hurst has more than twenty-five years experience in the biopharmaceutical industry and has contributed to the success of numerous complex and challenging healthcare projects. As the Chief Business Officer for The Immune Tolerance Institute (2007-2011), he helped establish a human immune monitoring institute for The Regents of the University of California that discovers and develops immune biomarkers. As a consultant to The World Bank and BI

Prior to joining Savant, Dr. Freeman was a drug development consultant for biotechnology and pharmaceutical companies. He served as Vice President of Clinical Development at Onyx Pharmaceutical (2001-2006) and was head of both clinical development and operations, which executed the clinical trials for renal cell, melanoma, liver, lung, and colorectal cancer. He successfully performed the Phase 1, 2, and 3 studies, which lead to NDA approval of

Prior to joining Savant, Dr. Boardman was a partner in the Enterprise Catalyst Group (ECG), a biopharmaceutical practice. Prior to joining ECG, he was Vice President of Operations for Sequential, Inc. (2002-2004) and was Vice President of Process Development and Manufacturing for Inhale Therapeutic Systems, Inc., (now Nektar Therapeutics, Inc.) (1995-2002). His experience spans both large pharmaceutical organizations and startup biotechnology c

Dr. Lo held various positions at AstraZeneca within the Drug Discovery, Clinical Development and International Sales and Marketing Organizations, including, from 2010 to 2012, that of Senior Director and Product Development Team Leader at MedImmune LLC (an AstraZeneca subsidiary). Dr. Lo completed his PhD at Imperial College, University of London, in 1980. He was a postdoctoral fellow in the laboratory of Solomon H. Snyder at the Johns Hopkins U

Prior to joining Savant, Ms. Bonelle was an independent consultant within the health care industry working to establish development compliant quality and transitioning early phase quality systems to commercially compliant systems for drug products, biologic products, medical devices and OTC drugs. Ms. Bonelle has over thirty years of experience developing quality organizations within startup firms as well as transitioning to commercial operation